p16INK4A Hypermethylation Is Associated with Hepatitis Virus Infection, Age, and Gender in Hepatocellular Carcinoma
Tóm tắt
Purpose: The tumor suppressor gene p16INK4A is mainly inactivated by an epigenetic change involving promoter hypermethylation in hepatocarcinogenesis. The possible clinical impact of p16INK4A methylation and the potential risk factors for this epigenetic alteration have not been thoroughly investigated.
Experimental Design: We studied the methylation status and mRNA and protein expression of p16INK4A in 50 hepatocellular carcinomas and corresponding nonneoplastic liver lesions using methylation-specific PCR, reverse transcription-PCR, and immunohistochemical techniques.
Results: p16INK4A hypermethylation was observed in 58% (29 of 50) of the hepatocellular carcinomas and 16% (6 of 38) of the corresponding chronic hepatitis and cirrhosis tissue samples. p16INK4A methylation was significantly associated with mRNA and protein expression (P < 0.001 and P = 0.003, respectively). All of the p16INK4A-methylated tumors were positive for hepatitis B virus or hepatitis C virus markers, but none of the virus-negative tumors exhibited p16INK4A methylation (P = 0.006). The frequency of p16INK4A hypermethylation tended to be higher in hepatitis C virus-related tumors (23 of 32, 72%) than in hepatitis B virus-related tumors (6 of 13, 46%; P = 0.1). Aberrant methylation of p16INK4A was also related significantly to increasing age, female gender, and normal levels of serum PIVKA-II (P = 0.02, 0.04, and 0.04, respectively). No statistically significant difference in survival was observed between patients with p16INK4A hypermethylation and those without.
Conclusions: Our observations suggest that p16INK4A hypermethylation may contribute to hepatocarcinogenesis from an early stage and that multiple risk factors, such as viral infections, age, and gender, may be associated with p16INK4A hypermethylation in hepatocarcinogenesis.
Từ khóa
Tài liệu tham khảo
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond) 1993;366:704-7.
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond) 1994;368:753-6.
Merlo A, Herman JG, Mao L, et al 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
Hui AM, Sakamoto M, Kanai Y, et al Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology 1996;24:575-9.
Kita R, Nishida N, Fukuda Y, et al Infrequent alterations of the p16INK4A gene in liver cancer. Int J Cancer 1996;67:176-80.
Biden K, Young J, Buttenshaw R, et al Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology 1997;25:593-7.
Chaubert P, Gayer R, Zimmermann A, et al Germ-line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 1997;25:1376-81.
Liew CT, Li HM, Lo KW, et al High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 1999;18:789-95.
Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H. p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 1999;116:394-400.
Jin M, Piao Z, Kim NG, et al p16 is a major inactivation target in hepatocellular carcinoma. Cancer (Phila) 2000;89:60-8.
Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 2001;33:561-8.
Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Frequent k- ras-2 mutations and p16INK4A methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 2001;84:982-9.
Kaneto H, Sasaki S, Yamamoto H, et al Detection of hypermethylation of the p16INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 2001;48:372-7.
Peng CY, Chen TC, Hung SP, et al Genetic alterations of INK4α/ARF locus and p53 in human hepatocellular carcinoma. Anticancer Res 2002;22:1265-71.
Shen L, Ahuja N, Shen Y, et al DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst (Bethesda) 2002;94:755-61.
Roncalli M, Bianchi P, Bruni B, et al Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 2002;36:427-32.
Sobin LH Wittekind C eds. . TNM classification of malignant tumors 200281-3. Wiley-Liss New York
Liver Cancer Study Group of Japan. . Classification of primary liver cancer 199728-37. Kanehara Tokyo
Hui AM, Shi YZ, Li X, Takayama T, Makuuchi M. Loss of p16INK4 protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression. Cancer Lett 2000;154:93-9.
Belinsky SA, Nikula KJ, Palmisano WA, et al Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-6.
Kang GH, Shim YH, Jung HY, Kim WH, Ro JY, Rhyu MG. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001;61:2847-51.
Kim DH, Nelson HH, Wiencke JK, et al p16INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-24.
Kang GH, Lee S, Kim WH, et al Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 2002;160:787-94.
Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003;163:1101-7.
Heller H, Kämmer C, Wilgenbus P, Doerfler W. Chromosomal insertion of foreign (adenovirus type 12, plasmid, or bacteriophage) DNA is associated with enhanced methylation of cellular DNA segments. Proc Natl Acad Sci USA 1995;92:5515-9.
Röcken C, Carl-McGrath S. Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis 2001;19:269-78.
Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994;7:536-40.
Issa JP, Vertino PM, Boehm CD, Newsham IF, Baylin SB. Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 1996;93:11757-62.
Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998;58:5489-94.
Li Q, Jedlicka A, Ahuja N, et al Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene 1998;16:3197-202.
Wiencke JK, Zheng S, Lafuente A, et al Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomark Prev 1999;8:501-6.
El-Naggar AK, Lai S, Clayman G, et al Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 1997;151:1767-74.
Zheng S, Chen P, McMillan A, et al Correlations of partial and extensive methylation at the p14ARF locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis (Lond) 2000;21:2057-64.